Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
Rhea-AI Summary
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced it will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 26, 2025, before U.S. markets open. The company's management will host a live webcast at 8 a.m. Eastern Time to discuss financial and operating results.
Participants can access the webcast through the Investor Relations section of Madrigal's website and are advised to register 15 minutes before the scheduled start. A replay will be available approximately two hours after the live event.
Positive
- None.
Negative
- None.
News Market Reaction – MDGL
On the day this news was published, MDGL gained 2.53%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register here at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
When will Madrigal Pharmaceuticals (MDGL) release Q4 and full-year 2024 earnings?
What time is Madrigal Pharmaceuticals' (MDGL) Q4 2024 earnings call?
How can investors access Madrigal Pharmaceuticals' (MDGL) Q4 2024 earnings webcast?
Will there be a replay available for Madrigal's (MDGL) Q4 2024 earnings webcast?
